Lone Ottesen

Dr Ottesen is a highly experienced drug developer with extensive experience across the global oncology and immune-oncology drug development spectrum with nearly 20 years in the pharmaceutical industry in both early- and late-phase development. Lone got her MD and PhD at Aarhus University in Denmark and has held roles of increasing seniority in GSK, Eisai and latest AstraZeneca where she was the Global Clinical Head for two assets in pivotal clinical development as well as leading the development of durvalumab in breast and gynecological cancers. Lone joined Targovax as Chief Development officer, and transitioned to Chief Medical Officer in 2022. Lone is the medical and clinical head for all Targovax Clinical Development activities across the portfolio.